<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60389">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01904435</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG 203</org_study_id>
    <secondary_id>Kayla Rosati</secondary_id>
    <secondary_id>401-863-3000</secondary_id>
    <nct_id>NCT01904435</nct_id>
  </id_info>
  <brief_title>Cetuximab, Paclitaxel, Carboplatin And Radiation For Esophageal, Gastroesophageal Junction And Gastric Cancer</brief_title>
  <official_title>BrUOG-E/G-203 CETUXIMAB, PACLITAXEL, CARBOPLATIN AND RADIATION FOR ESOPHAGEAL, GASTROESOPHAGEAL JUNCTION AND GASTRIC CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study of cetuximab, paclitaxel, carboplatin and radiation for esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cetuximab, paclitaxel, carboplatin weekly for 6 weeks with 50.4 Gy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients with clinical complete response change from treatment to follow-up</measure>
    <time_frame>completion of chemo/radiation and 6 months post drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>pathology used for assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with toxicity throughout study treatment</measure>
    <time_frame>weekly during chemo/radiation and at completion of chemo/radiation and during follow-up for surivival (maximum of 5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy/radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy/Radiation</intervention_name>
    <arm_group_label>chemotherapy/radiation</arm_group_label>
    <other_name>Cetuximab, paclitaxel, carboplatin and radiation then surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nonmetastatic esophageal or gastric cancer

        Exclusion Criteria:

        metastatic disease -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 17, 2013</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>howard safran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cetuximab</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
